Systemic administration of Resolvin D1 reduces cancer‐induced bone pain in mice: Lack of sex dependency in pain development and analgesia
Cancer Medicine · 2024
DOI: 10.1002/cam4.70077 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Alyssa Flippen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diagnostic and Biological Sciences, School of Dentistry, University of Minnesota, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Bone Neoplasms, Cancer Pain, Docosahexaenoic Acids, Hyperalgesia. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Aims
Bone cancer produces severe pain that is treated with opioids, but serious side effects limit opioid utilization. There is therefore a need to develop effective and safe non‐opioid alternatives. The lipid mediator, Resolvin D1 (RvD1), could be a prospective candidate for cancer pain treatment. To assess RvD1 and other potential candidates, appropriate animal models that recapitulate clinical features must be used. Although several preclinical models of cancer pain have been developed, the influence of sex on the development of cancer pain and the effectiveness of RvD1 have not been studied.
Results
Using a mouse model of fibrosarcoma growth in and around the calcaneus bone, we demonstrated that the mechanical hyperalgesia in the tumor‐bearing hind paw develops independently of sex, except that it developed a little sooner in female mice. A single intravenous injection of RvD1 (0.001–10 μg/kg) decreased hyperalgesia in both sexes with similar potency (ED 50 = 0.0015 μg/kg) and efficacy. Repeated daily administration of 10 μg/kg RvD1 prolonged the analgesic effect and completely abolished hyperalgesia. This was also independent of sex.
Conclusion
In this preclinical mouse model of bone cancer pain, the development of pain and the analgesic effectiveness of RvD1 are not influenced by sex.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Diagnostic and Biological Sciences, School of Dentistry, University of Minnesota, Minneapolis, Minnesota, USA.
ORCID-Profile: Sergey G Khasabov
Förderung
- NCI NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Flippen, A., Khasabova, I. A., Simone, D. A., & Khasabov, S. G. (2024). Systemic administration of Resolvin D1 reduces cancer‐induced bone pain in mice: Lack of sex dependency in pain development and analgesia. Cancer Medicine. https://doi.org/10.1002/cam4.70077
Vancouver
Flippen A, Khasabova IA, Simone DA, Khasabov SG. Systemic administration of Resolvin D1 reduces cancer‐induced bone pain in mice: Lack of sex dependency in pain development and analgesia. Cancer Medicine. 2024. doi:10.1002/cam4.70077
BibTeX
@article{Flippen2024,
author = {Flippen, Alyssa and Khasabova, Iryna A and Simone, Donald A and Khasabov, Sergey G},
title = {Systemic administration of Resolvin D1 reduces cancer‐induced bone pain in mice: Lack of sex dependency in pain development and analgesia},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.70077}
}
EUVIMED